# **Supplementary Information**

### Comparative profiling of analog targets: a case study on resveratrol

### for mouse melanoma metastasis suppression

Xiao Chen,<sup>1</sup> Wei Li,<sup>1</sup> Chengchao Xu,<sup>2</sup> Jie Wang,<sup>1</sup> Bo Zhu,<sup>1</sup> Qilai Huang,<sup>1</sup> Dianhua Chen,<sup>1</sup> Jianfei Sheng,<sup>3</sup> Yong Zou,<sup>3</sup> Yew Mun Lee,<sup>2</sup> Renxiang Tan,<sup>1</sup> Pingping Shen,<sup>1</sup> Yin Kwan Wong,<sup>2</sup> Qingsong Lin,<sup>2</sup> Jigang Wang,<sup>4,5,2,\*</sup> and Zichun Hua<sup>1,\*</sup>

- The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, China
- Department of Biological Science, National University of Singapore, Singapore, 117543, Singapore
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China
- Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China

\*Corresponding authors: zchua@nju.edu.cn (Z.H.), wangjigang@u.nus.edu (J.W.)

## **Supplementary Figures**



Figure S1. Distribution of targets of RSV and RSVN in B16F10 cells



Figure S2. Transcription activity of FAK promoter truncations



Figure S3. Transcription factor binding sites analysis of FAK promoter using P-Match software and the gene reporter plamids used in the study.



Figure S4. Transcription activity of the mutations of FAK promoter from dualluciferase assay.



Figure S5. Expression level of USF1 and FAK in B16F10 cells with or without the treatment of USF1's siRNA.

### **Supplementary Methods**

#### Synthesis of RSVT



#### Synthesis of PTER



#### Synthesis of RSVN



3-(3,5-Dimethoxyphenyl)-7-hydroxy-2H-chromen-2-one Triethylamine (8 ml) was added to a solution of 2-(3,5-dimethoxyphenyl)acetic acid (4 g, 20 mmol) and 3,5dihydroxybenzaldehyde (2.8 g, 20 mmol) in acetic anhydride (20 mL) The mixture was heated to 120  $^{\circ}$  and stirred for 8 h. After cooling, it was poured into ice water, stirred, and stored for 4 h. The precipitated yellowish solid was filtered, washed with water, dried, and recrystallized from ethyl acetate. The title compound 4.5 g (75%) was obtained as a light yellow solid. LC-MS show M+1 (299). To a solution of 3-(3,5-Dimethoxyphenyl)-7-hydroxy-2H-chromen-2-one (2 g, 6.7 mmol) in DCM (50 mL) was drop wise added BBr<sub>3</sub> (5 g, 20.1 mmol) at 0 °C. The mixture was stirred at room temperature for 3 h under Ar atmosphere. Then quenching by H<sub>2</sub>O at – 10 °C , adjusted pH=8 by NaHCO<sub>3</sub> (aq), extracted with EA for three times, the organic phase was dried and concentrated, the residue was purified by column chromatography with PE:EA=1:1 to give the title compound as a light yellow solid (1.2 g, 65%). LC-MS show M+1 (271).

#### Synthesis of RSV-P



To a solution of biotin (50 mg, 2.05 mmol) in DMF (20 mL) was added HATU (800 mg, 2.1 mmol) at 0 °C. Then resveratrol (502 mg, 2.2 mmol) and DIPEA (323 mg, 2.5 mmol) were added under Ar atmosphere. The mixture was stirred for 3 h at room temperature. The mixture was concentrated in vacuo, the residue was purified by column chromatography with DCM :  $CH_3OH = 4 : 1$  to give the title compound as a white solid (110 mg, 11%). LC-MS show M+1 (454.8).

#### Synthesis of RSVN-P



To a solution of biotin (50 mg, 2.05 mmol) in DMF (20 mL) was added HATU (800 mg, 2.1 mmol) at 0 °C. Then NJ-2-4 (600 mg, 2.2 mmol) and DIPEA (323 mg, 2.5 mmol) were added under Ar atmosphere. The mixture was stirred for 3 h at room temperature. The mixture was concentrated in vacuo, the residue was purified by column chromatography with DCM:  $CH_3OH = 5:1$  to give the title compound as a white solid (110 mg, 11%). LC-MS show M+1 (496.9).

### NMR spectra





# Mass spectrum



